Skip to main content

Galapagos Completes $5.42M Acquisition of DPI’s Drug Discovery Operations

NEW YORK (GenomeWeb News) - Galapagos said today that it has completed its €4.25 million ($5.42 million) acquisition of Discovery Partners International's drug discovery operations, which will now be part of Galapagos' service division, BioFocus DPI.
 
As a result of the acquisition, Mechelen, Belgium-based Galapagos has increased its 2006 revenue guidance to the range of €33 million to €38 million ($42 million to $48 million), from the range of €25 million to €30 million ($32 million to $ 38 million).
 
The operations acquired by Galapagos include DPI discovery services sites in San Diego; South San Francisco, Calif.; Basel, Switzerland; and Heidelberg, Germany.
 
Galapagos has also acquired DPI's Tokyo sales office.
 
Galapagos announced its intention to acquire the discovery group in mid-June.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.